



14th August 2019

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai 400 001

The Secretary
The National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East,
Mumbai 400 050

Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Dear Sirs

The unaudited financial results of the Company for the quarter and half year ended 30th June 2019 were approved by the Board of Directors of the Company at its meeting held on 29th July 2019 and published on 31st July 2019. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2019 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For SANOFI INDIA LIMITED



GIRISH TEKCHANDANI
COMPANY SECRETARY

SANOFI INDIA LIMITED
Related Party Transactions for the half year ended 30th June 2019

Related Party Disclosures

i. Parties where control exists:

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the year.

Sanofi-Aventis Singapore Pte. Limited
 Francopia S.A.R.L.
 Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Groupe S.A.
 Sanofi Lanka Limited
 Sanofi-aventis U.S.Inc.
 Sanofi Chimie S.A
 Sanofi Pasteur India Private Limited
 Sanofi-Synthelabo (India) Private Limited
 Sanofi Winthrop Industrie S.A.
 Sanofi-Aventis Pakistan Limited
 Sanofi-Aventis Recherche et Développement S.A.
 Sanofi-Aventis Spa
 Shantha Biotechnics Private Limited
 Sanofi India Limited Provident Fund

iii. Key management personnel of the Company for the year

Mr. Rajaram Narayanan - Managing Director
 Mr. Ashwani Sood - Whole Time Director (till the closure of business hours of May 31, 2019)
 Mr. Charles Billard - Whole Time Director and CFO
 Mr. Girish Tekchandani - Company Secretary

iv. Non-Executive Directors

Mr. Thomas Rouckout
 Mr. Cyril Grandchamp-Desraux
 Dr. Shailesh Ayyangar


v. Independent Directors

Mr. Aditya Narayan
 Mr. Rangaswamy R. Iyer
 Mrs. Usha Thorat

vi. Transactions during the year

(₹ in Million)

| Particulars | June 30, 2019 |
|---|---------------|
| Ultimate Holding Company | |
| Dividend paid | * |
| Holding Company | |
| Dividend paid | 918 |
| Other related Parties | |
| Sale of Products | |
| Sanofi-Aventis Singapore Pte. Limited | 3,835 |
| Others | 303 |
| Total | 4,138 |
| Purchase of Raw Materials and Traded Goods | |
| Sanofi-Aventis Singapore Pte. Limited | 3,480 |
| Others | 8 |
| Total | 3,488 |
| Expenses recharged to other companies | |
| Sanofi-Synthelabo (India) Private Limited | * |
| Sale of Services | |
| Sanofi-Synthelabo (India) Private Limited | 592 |
| Sanofi Pasteur India Private Limited | 96 |
| Sanofi Winthrop Industrie S.A. | 69 |
| Others | 34 |
| Total | 791 |
| Rent Income | |
| Sanofi-Synthelabo (India) Private Limited | 4 |
| Loans repaid | |
| Sanofi Pasteur India Private Limited | 500 |
| Mr. Ashwani Sood | * |
| Total | 500 |
| Interest income on loans | |
| Shantha Biotechnics Private Limited | 210 |
| Sanofi Pasteur India Private Limited | 5 |
| Total | 215 |



| Particulars | June 30, 2019 |
|---|---------------|
| Expenses recharged by other companies | |
| Sanofi-Synthelabo (India) Private Limited | 28 |
| Sanofi Winthrop Industrie S.A. | 10 |
| Sanofi-Aventis Groupe S.A. | 6 |
| Others | 5 |
| Total | 49 |
| Contribution to In-house Trust for Post Employment Benefits - Provident Fund | |
| Sanofi India Limited Provident Fund # | 138 |
| Payment towards Intangibles under development | |
| Sanofi-Synthelabo (India) Private Limited | 7 |
| Key Management Personnel Remuneration | |
| Remuneration | |
| Mr. Rajaram Narayanan | 19 |
| Mr. Ashwani Sood | 5 |
| Mr. Charles Billard | 9 |
| Mr. Girish Tekchandani | 6 |
| Total | 39 |
| Share based benefit | |
| Mr. Rajaram Narayanan | 6 |
| Mr. Charles Billard | 1 |
| Total | 7 |
| Sitting Fees to Independent Directors | |
| Mr. Aditya Narayan | * |
| Mr. Rangaswamy R. Iyer | * |
| Ms. Usha Thorat | * |
| Total | 1 |
| Commission to Independent Directors | |
| Mr. Aditya Narayan | 2 |
| Mr. Rangaswamy R. Iyer | 1 |
| Ms. Usha Thorat | 1 |
| Mr. A. K. R. Nedungadi (upto January 15, 2018) | * |
| Total | 3 |

* denotes figure less than a million

Including contribution by employees.

Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year six month ended June 30, 2019, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

vii. Outstanding as at June 30, 2019

(₹ in Million)

| Particulars | June 30, 2019 |
|---|---------------|
| Other related Parties | |
| Trade Receivables | |
| Sanofi-Aventis Singapore Pte. Limited | 1,193 |
| Sanofi-Synthelabo (India) Private Limited | 109 |
| Others | 218 |
| Total | 1,520 |
| Trade Payables | |
| Sanofi-Aventis Singapore Pte. Limited | 1,148 |
| Sanofi-Synthelabo (India) Private Limited | 158 |
| Others | 7 |
| Total | 1,313 |
| Others Payables | |
| Sanofi-Aventis Singapore Pte. Limited | 36 |
| Total | 36 |
| Loans receivable | |
| Shantha Biotechnics Private Limited# | 4,450 |
| Mr. Ashwani Sood * | * |
| Total | 4,450 |

#Loans given to Shantha Biotechnics Private Limited at the rate of interest of 9.5% p.a.

Maximum balance outstanding during the year ₹ 4,450 Million

The said loans have been proposed to be utilized by Shantha Biotechnics Private Limited for business purpose.

The Loan have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company). The Maturity Date of same is April 15, 2020.

* Given as per the Company's policies for employees.

